Latest News-Innovent Biologics,Inc Mediaroom_Page

Innovent Announces First Patient Dosed in Phase 2 Pivotal Trial of IBI310 (CTLA-4) combined with TYVYT® (sintilimab injection) for the treatment of second-line or above Advanced Cervical Cancer

SAN FRANCISCO and SUZHOU, China, Dec. 11, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2020-12-11 09:02 7414

Innovent Announces Parsaclisib Treatment Results in High Rate of Rapid and Durable Responses in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

SAN FRANCISCO and SUZHOU, China, Dec. 8, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent")...

2020-12-08 08:00 4786

Innovent Announces NMPA Granted New Indication Approval for SULINNO® (Adalimumab Injection) in China for the Treatment of Polyarticular Juvenile Idiopathic Arthritis

SAN FRANCISCO and SUZHOU, China, Nov. 23, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ...

2020-11-23 18:34 9582

Innovent Releases Phase 3 Results of TYVYT® (Sintilimab Injection) in Combination with BYVASDA® (Bevacizumab Biosimilar Injection) as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma (HCC) at ESMO ASIA Virtual Congress 2020

SAN FRANCISCO and SUZHOU, China, Nov. 23, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2020-11-23 08:00 5877

Innovent Announces the Results of the Phase I Clinical Trial of IBI302, a First-in-class Ophthalmic Recombinant Human Anti-VEGF and Anti-Complement Bi-specific Fusion Protein for Neovascular Age-Related Macular Degeneration at 2020 American Academy of Ophthalmology

SAN FRANCISCO and SUZHOU, China, Nov. 16, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2020-11-16 08:00 5688

Innovation Drives Excellence, Innovent Successfully Held 2020 Virtual R&D Day

SAN FRANCISCO and SUZHOU, China, Nov. 11, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2020-11-11 08:00 8258

Innovation Drives Excellence, Innovent Successfully Held 2020 Virtual R&D Day

Innovent Releases Phase 1a Results of CD47 Monoclonal Antibody (Letaplimab) in Monotherapy for Advanced Malignancies at SITC 2020

SAN FRANCISCO, U.S. and SUZHOU, China, Nov. 11, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Inn...

2020-11-11 08:00 6964

Innovent and Lilly Jointly Announce Results of Seven Clinical Studies of TYVYT® (sintilimab injection) to Be Presented at the ESMO ASIA Congress 2020

SAN FRANCISCO and SUZHOU, China, Nov. 5, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent")...

2020-11-05 08:00 6071

Innovent Announces the Appointment of Dr. Yong Jun Liu as the President of the Group

SAN FRANCISCO and SUZHOU, China, Oct. 15, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2020-10-15 08:00 13228

Innovent and Lilly Jointly Announce the NMPA Granted Marketing Approval for HALPRYZA® (Rituximab Injection) in China

SAN FRANCISCO and SUZHOU, China, Oct. 9, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (...

2020-10-09 19:14 11793

Innovent Announces the Effectiveness of the Expanded Global Collaboration with Lilly on TYVYT® (sintilimab injection) Following the Expiration of HSR Act Waiting Period

SAN FRANCISCO and SUZHOU, China, Oct. 7, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent")...

2020-10-07 08:00 14464

Innovent Biologics Announces to Host 2020 Virtual R&D Day on November 10th

SAN FRANCISCO and SUZHOU, China, Sept. 28, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent...

2020-09-28 12:13 5667

TYVYT® (Sintilimab Injection) in Combination with BYVASDA® (Bevacizumab Injection) ORIENT-32 Study Met Its Primary Endpoints of Progression-Free Survival and Overall Survival in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma (HCC)

SAN FRANCISCO and SUZHOU, China, Sept. 28, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent...

2020-09-28 10:15 6349

Innovent and Lilly Jointly Release Phase 3 Results of TYVYT® (Sintilimab Injection) in Combination with GEMZAR® (Gemcitabine) and Platinum Chemotherapy as First-Line Treatment for Squamous Non-Small Cell Lung Cancer at ESMO Virtual Congress 2020

SAN FRANCISCO and SUZHOU, China, Sept. 21, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innoven...

2020-09-21 08:00 7700

Innovent and Lilly Release Biomarker Results of TYVYT® (Sintilimab Injection) in Combination with ALIMTA® (Pemetrexed) and Platinum Chemotherapy as First-Line Treatment for Nonsquamous Non-Small Cell Lung Cancer at ESMO Virtual Congress 2020

SAN FRANCISCO and SUZHOU, China, Sept. 21, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innoven...

2020-09-21 08:00 6704

Innovent and Lilly Jointly Announce Results of Six Clinical Studies of TYVYT® (sintilimab injection) to be Presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020

SAN FRANCISCO and SUZHOU, China, Sept. 14, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent...

2020-09-14 18:00 13065

Innovent Announces NMPA Granted Marketing Approval for SULINNO® (Adalimumab Injection) in China

SAN FRANCISCO, U.S. and SUZHOU, China, Sept. 3, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Inno...

2020-09-03 17:50 4917

Innovent Announces First Subject Dosed in the Phase 1 Clinical Trial of Anti-IL-23 Monoclonal Antibody

SAN FRANCISCO, and SUZHOU, China, Aug. 31, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent)...

2020-09-01 08:00 2433

Innovent Announces the Results of the Phase 1/2 Clinical Study of PCSK9 Antibody Tafolecimab at the European Society of Cardiology Annual Conference

SAN FRANCISCO and SUZHOU, China, Aug. 31, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2020-08-31 08:00 5867

Innovent Announces Financial Results for Six Months Ended June 30, 2020 and Corporate Progress

SAN FRANCISCO, U.S. and SUZHOU, China, Aug. 27, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (...

2020-08-27 09:37 10447